Fig. 6
Treatment of CT2A-dmEGFRvIII-Luc intracranial tumors with D2C7-IT and αPD-1/αCTLA-4 combinations. (a) Survival curves and median survival estimates for CT2A-dmEGFRvIII-Luc tumor-bearing mice treated with vehicle control, D2C7-IT, αPD-1, and αCTLA-4 mono or combination therapies. The p-values were generated from the generalized Wilcoxon test and are not adjusted for multiple testing. (b) Median survival was estimated for mice surviving symptom-free to Day 100 post-tumor implantation from different treatment groups and were re-challenged in the contralateral hemisphere of the brain with 1.5 × 105 CT-2A-dmEGFRvIII-Luc cells. C57BL/6 J mice (N = 5) were used as naïve controls